Delgocitinib

Delgocitinib
Clinical data
Trade names	Corectim
Other names	JTE-052; JTE-052A
ATC code	D11AH11 (WHO) ;
Legal status
Legal status	Rx-only in Japan;
Identifiers
	IUPAC name 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile;
CAS Number	1263774-59-9;
PubChem CID	50914062;
DrugBank	DB16133;
ChemSpider	59718502;
UNII	9L0Q8KK220;
KEGG	D11046;
Chemical and physical data
Formula	C16H18N6O
Molar mass	310.361 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2;
	InChI InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1; Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N;

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.^[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.^[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.^[2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.^[3]

References

^ ^a ^b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Dhillon-1] Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.

[2] Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.

[3] Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.

[1]

[2]

[3]

Delgocitinib

References

Navigation menu

Search